Inactive Instrument

Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
French Drugmaker Ipsen Concludes Albireo Pharma Takeover MT
Albireo Pharma, Inc. Announces Board Changes CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders. CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance MT
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome DJ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application CI
Insider Sell: Albireo Pharma MT
Guggenheim Downgrades Albireo Pharma to Neutral From Buy MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68 MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49 MT
North American Morning Briefing : Stock Futures -2- DJ
Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating MT
HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42 MT
North American Morning Briefing : More Hawkish Fed -2- DJ
Top Midday Gainers MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Transcript : Albireo Pharma, Inc., Ipsen S.A. - M&A Call
Top Premarket Gainers MT
Wedbush Downgrades Albireo Pharma to Neutral From Outperform After News of Sale to Ipsen, Lowers Price Target to $42 From $53 MT
Albireo Pharma to be Acquired by Ipsen MT
France's Ipsen Moves to Broaden Rare Disease Portfolio Via $952 Million Purchase of Albireo MT
Chart Albireo Pharma, Inc.
More charts
Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
More about the company
  1. Stock
  2. Equities
  3. Stock Albireo Pharma, Inc. - Nasdaq
  4. News Albireo Pharma, Inc.
  5. Albireo Pharma Likely to Post Q1 Sales in Line With Guidance, Wedbush Says